User: Guest  Login
Title:

First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO

Document type:
Editorial Material
Author(s):
Rexer, H.; Retz, M.; Hammerer, P.
Journal title abbreviation:
Urologe A
Year:
2021
Journal volume:
60
Journal issue:
7
Pages contribution:
987-988
Fulltext / DOI:
doi:10.1007/s00120-021-01570-0
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/34255120
Print-ISSN:
0340-2592
TUM Institution:
Urologische Klinik und Poliklinik
 BibTeX